Use of ?-asparaginase in childhood ALL (Q29041017)

Europe PubMed Central

title

Use of ?-asparaginase in childhood ALL (English)

1 reference

https://doi.org/10.1016%2FS1040-8428%2898%2900015-8

27 March 2017

author name string

H Müller

series ordinal

1

1 reference

https://doi.org/10.1016%2FS1040-8428%2898%2900015-8

27 March 2017

publication date

August 1998

1 reference

https://doi.org/10.1016%2FS1040-8428%2898%2900015-8

Critical Reviews in Oncology Hematology

27 March 2017

published in

1 reference

https://doi.org/10.1016%2FS1040-8428%2898%2900015-8

27 March 2017

volume

28

1 reference

https://doi.org/10.1016%2FS1040-8428%2898%2900015-8

27 March 2017

issue

2

1 reference

https://doi.org/10.1016%2FS1040-8428%2898%2900015-8

27 March 2017

page(s)

97-113

1 reference

https://doi.org/10.1016%2FS1040-8428%2898%2900015-8

Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia

27 March 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Stereospecific asparaginases in smooth Brucella abortus, strain 19

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Comparative pharmacokinetic studies of three asparaginase preparations

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

L-asparaginase induced antithrombin III deficiency: evidence against the production of a hypercoagulable state

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

L-Asparaginase in Treatment of Acute Leukaemia and Lymphosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

l-Asparaginase: Inhibition of endogenous RNA polymerase activity regenerating liver

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

L -Asparaginase: Inhibition of Early Mitosis in Regenerating Rat Liver

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Delayed pancreatic pseudocyst formations. Long-term complication of L-asparaginase treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Loss of activity of Erwinia asparaginase on repeat applications

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Suppression of murine leukemias by L-asparaginase. Incidence of sensitivity among leukemias of various types: comparative inhibitory activities of guinea pig serum L-asparaginase and Escherichia coli L-asparaginase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Studies on the mechanism of tumor inhibition by L-asparaginase. Effects of the enzyme on asparagine levels in the blood, normal tissues, and 6C3HED lymphomas of mice: differences in asparagine formation and utilization in asparaginase-sensitive and

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Factors which may influence the effectiveness of L-asparaginases as tumor inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Characterization of apoptotic phenomena induced by treatment with L-asparaginase in NIH3T3 cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Diabetic metabolic disorders in the treatment of leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

L-Asparaginase EC-2 from Escherichia coli. Some substrate specificity characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Two L-asparaginases from Escherichia coli B. Their separation, purification, and antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

L-asparaginase: clinical, biochemical, pharmacological, and immunological studies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Hyperglycemia associated with the therapeutic use of L-asparaginase: possible role of insulin receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

L-Asparaginase and L-Asparagine Metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

The effect of L-asparaginase on lipid metabolism during induction chemotherapy of childhood lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

The action of Pseudomonas fluorescens extracts on asparagine and asparagine derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

A method of selecting for auxotrophic mutants of HeLa cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Polymer conjugates. Pharmacokinetic considerations for design and development

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children--evidence of a complement-mediated mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Diabetes in patients treated with asparaginase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Transient diabetes mellitus secondary to L-asparaginase therapy in acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

The Enzymic Deamidation of Asparagine in the Higher Plants

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Hydrolysis of amides by extracts from Mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Methotrexate/L-asparaginase combination chemotherapy for patients with acute leukemia in relapse: a study of 36 children

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Clinical pharmacologic studies of L-asparaginase.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Clinical Pharmacology of Intramuscularly Administered l‐Asparaginase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

1 reference

7 January 2021

Psychiatric symptoms associated with L-asparaginase administration

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Transient hyperlipidemia during treatment of ALL with L-asparaginase is related to decreased lipoprotein lipase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Treatment of acute leukemia with L-asparaginase--preliminary results on 84 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Diabetes mellitus secondary to l-asparaginase therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Myelosuppressive Effect of Colaspase (L-Asparaginase) in Initial Treatment of Acute Lymphoblastic Leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Toxicity of L-asparaginase in children with advanced leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

The effect of E. Coli L-asparaginase on oral glucose tolerance and insulin release in man

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Acute encephalopathy and hyperammonaemia complicating treatment of acute lymphoblastic leukaemia with asparaginase.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Methotrexate and asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia of childhood

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Inactivation of complement by L-asparaginase preparations not correlated with enzyme content.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

The asparagine deamidase of Bacillus coagulans and Bacillus stearothermophilus

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

TUMOR INHIBITORY EFFECT OF L-ASPARAGINASE FROM ESCHERICHIA COLI

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Fatal case of L-asparaginase induced pancreatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Electroencephalogram Changes Secondary to Asparaginase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Nation-wide randomized comparative study of doxorubicin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Dual requirement of Walker carcinosarcoma 256 in vitro for asparagine and glutamine

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Changes in coagulation and fibrinolysis in childhood ALL: a two-step dose reduction of one E. coli asparaginase preparation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Resistance to activated protein C (APCR) in children with acute lymphoblastic leukaemia--the need for a prospective multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Toxicity of E. coli L-asparaginase in man

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Comparison of daily versus weekly L-asparaginase for the treatment of childhood acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Altered von Willebrand factor molecule in children with thrombosis following asparaginase-prednisone-vincristine therapy for leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Letter: Toxicity of asparaginases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Surgical pancreatic complications induced by L-asparaginase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Changes in hemostatic and fibrinolytic proteins in patients receiving L-asparaginase therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Two L-asparaginases from E. coli and their action against tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

L-asparaginase activity in plasma and other biological fluids

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

L-asparaginase and pancreatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

A METABOLIC DIFFERENCE BETWEEN TWO LINES OF LYMPHOMA 6C3HED CELLS IN RELATION TO ASPARAGINE

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Use of L-asparaginase and cytosine arabinoside for refractory acute lymphocytic leukemia with particular reference to T-cell leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

L-asparaginase kills lymphoma cells by apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

[Changes in blood coagulation in treatment with ALL-BFM-90 and NHL-BFM-90 protocols]

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

L-asparaginase therapy in children with advanced leukemia. The Southwest Cancer Chemotherapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Antitumor enzyme: polyethylene glycol-modified asparaginase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Asparaginase and Glutaminase Activities of Bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

A new L-asparaginase with antitumour activity?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Latent onset of clinical pancreatitis in children receiving l-asparaginase therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

Purification and properties of asparaginase from escherichia coli B.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900015-8

1 reference

7 January 2021